Related Experiment Video
Updated: May 14, 2026
Retroductal Submandibular Gland Instillation and Localized Fractionated Irradiation in a Rat Model of Salivary Hypofunction
Published on: April 24, 2016
Hypofractionated palliative radiotherapy for advanced head and neck cancer: the IHF2SQ regimen
Laurie Monnier1, Emmanuel Touboul, Catherine Durdux
1Department of Radiation Oncology, Tenon Hospital, Assistance Publique - Hôpitaux Universitaires Paris Est, University Pierre et Marie Curie Paris VI, Paris, France.
Background:
Standard treatment for unresectable advanced head and neck squamous cell carcinoma is chemoradiotherapy, which can be toxic, particularly among patients with coexisting medical conditions. We report our experience with the hypofractionated radiotherapy regimen Irradiation HypoFractionnée 2 Séances Quotidiennes (IHF2SQ).
Methods:
We retrospectively reviewed 78 patients treated with the IHF2SQ regimen. Radiotherapy was administrated as 2 fractions of 3 Gy per day (days 1 and 3), during the first, third, fifth, and seventh week of treatment with concurrent platinum-based chemotherapy.
Results:
Tolerance was excellent. Forty-one patients had complete or partial response. Median overall survival (OS) was 12.9 months and median progression-free survival (PFS) was 10.3 months. One-year OS, specific survival (SS), and PFS were 58%, 71%, 51.5%, respectively. Independent predictive factors increasing the PFS were response to chemoradiotherapy, male sex, and laryngeal tumor location.
Conclusions:
This regimen is an alternative to conventional chemoradiotherapy with good response rates and acceptable toxicity for selected patients.
